LUCENT-1: Mirikizumab Sees Phase 3 Success in UC Treatment

Mirikizumab targets a subunit of interleukin 23, which has shown promise in other conditions.
Medscape Medical News

source https://www.medscape.com/viewarticle/969561?src=rss